Inovio Pharmaceuticals Reports 2015 Fourth Quarter and Year End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Maxim Affirms Inovio Pharma (INO) at 'Buy' Following Q4 Results, Asset Acquisition
March 14, 2016 2:45 PM EDTMaxim affirmed Inovio Pharma (Nasdaq: INO) with a Buy rating and $14 price target following Q4 results and acquisition of Bioject Medical Technologies' Needle-Free Injection Technology earlier Monday.
Analyst Jason Kolbert noted the following
Immune oncology: A phase III study for VGX-3100 is expected... More